×
About 37,840 results

ALLMedicine™ Gastric Cancer Center

Research & Reviews  13,935 results

Gastrectomy with or without omentectomy for gastric cancer: A systematic review and met...
https://doi.org/10.1016/j.surg.2021.10.052
Surgery Lin HW, Loh EW et. al.

Dec 4th, 2021 - Omentectomy is conventionally performed in the procedure of gastrectomy for gastric cancer. However, the clinical value and importance of omentectomy remain unclear. This meta-analysis investigated the benefits and safety of gastrectomy with or wi...

A tumour-resident Lgr5+ stem-cell-like pool drives the establishment and progression of...
https://doi.org/10.1038/s41556-021-00793-9
Nature Cell Biology; Fatehullah A, Terakado Y et. al.

Dec 4th, 2021 - Gastric cancer is among the most prevalent and deadliest of cancers globally. To derive mechanistic insight into the pathways governing this disease, we generated a Claudin18-IRES-CreERT2 allele to selectively drive conditional dysregulation of th...

The clinical impact of malnutrition on the postoperative outcomes of patients undergoin...
https://doi.org/10.1016/j.clnesp.2021.09.005
Clinical Nutrition ESPEN; Lee DU, Fan GH et. al.

Dec 4th, 2021 - Malnutrition is a prominent feature of gastric cancer patients who suffer from gastric outlet obstruction, impaired peristalsis, and cancer-mediated disruptions in metabolic hemostasis. In this study, we systematically evaluate the impact of malnu...

see more →

Guidelines  21 results

ACR Appropriateness Criteria® Epigastric Pain.
https://doi.org/10.1016/j.jacr.2021.08.006
Journal of the American College of Radiology : JACR; , Vij A et. al.

Nov 20th, 2021 - Epigastric pain can have multiple etiologies including myocardial infarction, pancreatitis, acute aortic syndromes, gastroesophageal reflux disease, esophagitis, peptic ulcer disease, gastritis, duodenal ulcer disease, gastric cancer, and hiatal h...

Hereditary diffuse gastric cancer: updated clinical practice guidelines.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116190
The Lancet. Oncology; Blair VR, McLeod M et. al.

Aug 8th, 2020 - Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour...

Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793.
https://doi.org/10.1097/AOG.0000000000003562
Obstetrics and Gynecology;

Nov 26th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheri...

British Society of Gastroenterology guidelines on the diagnosis and management of patie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709778
Gut Banks M, Graham D et. al.

Jul 7th, 2019 - Gastric adenocarcinoma carries a poor prognosis, in part due to the late stage of diagnosis. Risk factors include Helicobacter pylori infection, family history of gastric cancer-in particular, hereditary diffuse gastric cancer and pernicious anaem...

ACG and CAG Clinical Guideline: Management of Dyspepsia.
https://doi.org/10.1038/ajg.2017.154
The American Journal of Gastroenterology; Moayyedi P, Lacy BE et. al.

Jun 21st, 2017 - We have updated both the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG) guidelines on dyspepsia in a joint ACG/CAG dyspepsia guideline. We suggest that patients ≥60 years of age presenting with dy...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  552 results

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT05143970

Dec 3rd, 2021 - CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer. The trial will be conducted in two parts, Part I- Dose escalation: This part aims to identify the m...

Treatment of Malignant Tumors With NK Cell
https://clinicaltrials.gov/ct2/show/NCT05143125

Dec 3rd, 2021 - Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells, which are a type of lymphocytes that can non-specifically kill tumor cells and virus-infected cells without pre-sensitization. NK cells can not only directly kill ma...

Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Esophagogastric Junction Cancer
https://clinicaltrials.gov/ct2/show/NCT04443478

Dec 2nd, 2021 - Introduction: Lower mediastinal lymph node dissection has been adopted as standard by treatment guideline for adenocarcinoma of esophagogastric junction(AEJ), but the effect of laparoscopic mediastinal lymph node dissection remains unknown. The ai...

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03713905

Dec 2nd, 2021 - Dose escalation study: Primary purpose: To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer). Secondary purpose: 1. To characterize the pharmacokinetics(PK) profile...

Futibatinib in Patients With Specific FGFR Aberrations
https://clinicaltrials.gov/ct2/show/NCT04189445

Nov 30th, 2021 - Study TAS-120-202 is an open-label, multinational, 3-arm Phase 2 study evaluating the efficacy, safety, tolerability, PK, and pharmacodynamics of futibatinib in patients with FGFR aberrations. Eligible patients will be assigned to 1 of 3 treatment...

see more →

News  620 results

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer
https://www.onclive.com/view/niraparib-demonstrates-pfs-benefit-in-chinese-population-with-advanced-ovarian-cancer

Nov 30th, 2021 - First-line maintenance treatment with the PARP inhibitor niraparib (Zejula) yielded a clinically meaningful and statistically significant improvement in progression-free survival (PFS) vs placebo in Chinese patients with platinum-responsive advanc...

Hochster Shares Best Practices on Molecular Markers and Sequencing in Gastric Cancer
https://www.onclive.com/view/hochster-shares-best-practices-on-molecular-markers-and-sequencing-in-gastric-cancer

Nov 29th, 2021 - For patients with gastric cancer, utilizing molecular markers and genomic profiling is becoming more crucial in guiding treatment decisions, according to Howard S. Hochster, MD. For patients with gastric cancer, immunotherapy has become part of...

Ku Reviews Exciting ESMO Data in Gastric/GEJ Cancer
https://www.onclive.com/view/ku-reviews-exciting-esmo-data-in-gastric-gej-cancer

Nov 15th, 2021 - Welcome to OncLive On Air®! I’m your host today, Jessica Hergert. OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and...

ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas
https://www.onclive.com/view/esmo-2021-updates-in-gastroesophageal-and-gastric-adenocarcinomas

Nov 15th, 2021 - Data from the following clinical trials are discussed: LBA7 - Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcin...

Gastric Cancer Prevalent in Hereditary Breast Cancer Patients
https://www.medscape.com/viewarticle/962750

Nov 11th, 2021 - The risk of occult gastric adenocarcinoma is highly prevalent in hereditary lobular breast cancer (HLBC) families who harbor any type of CDH1 variant and this risk remains high in patients with no family history of gastric cancer, a prospective co...

see more →

Patient Education  6 results see all →